预约演示
更新于：2026-02-26
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-02-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,890
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
NCT07180979
Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial
NCT07350252
Postoperative Analgesia in Patients Undergoing Knee Replacement Surgery - a Study Comparing Intraoperative Local Infiltration Analgesia Only With Ultrasound-guided Nerve Blocks Added to Intraoperative Local Infiltration Analgesia, a Randomized Clinical Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,242
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-01Health Science Reports
Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study
Article
作者: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael
ABSTRACT:
Background and Aims:
We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.
Methods:
PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.
Results:
In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.
Conclusion:
Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.
2025-10-01Journal of PeriAnesthesia Nursing
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer
Article
作者: Yang, Qun ; Cheng, Feng ; Luo, Qian ; Rao, Li-Hao ; Yang, Ze-Xue ; Zheng, Li-Dong ; Cheng, Lei
PURPOSE:
This study aims to investigate the efficacy of a combination of ropivacaine hydrochloride and esketamine in paravertebral block (PVB), in providing analgesia and promoting the postoperative recovery of patients undergoing elective thoracoscopic radical lung cancer surgery.
DESIGN:
A randomized controlled trial was conducted involving 70 patients scheduled for elective thoracoscopic radical lung cancer surgery.
METHODS:
Participants were randomly assigned to either the esketamine group (K group) or the control group (C group). Patients in the K group were administered a combination of 0.1 mg/kg of esketamine and 0.5% ropivacaine for PVB, while patients in the C group received only 0.5% ropivacaine. The time interval between the patient's discharge from the postanesthesia care unit and the first press of the analgesic pump and the number of presses. Various parameters that were monitored included the patients' mean arterial pressure, heart rate, and oxygen saturation at different time points; levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood preoperatively and 6 hours postoperatively; pain assessed using the numeric rating scale scores.
FINDINGS:
Compared with group C, patients in group K had significantly longer intervals before their first postoperative analgesic pump press and significantly fewer effective analgesic pump presses in the 48-hour postoperative period. Resting numeric rating scale scores were significantly lower in group K at 24 and 48 hours postoperatively (both P < .05). In terms of postoperative recovery, sedation score during extubation was lower in group K compared with group C (P < .05). Patients in group K had significantly improved quality of recovery on the third day postoperatively (both P < .05). The levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood were significantly lower in group K than in group C 24 hours postoperatively, and the difference was statistically significant (P < .05).
CONCLUSIONS:
PVB with ropivacaine hydrochloride combined with esketamine effectively prolonged the time to the first analgesic pump use, reduced the overall analgesic pump requirement, and facilitated rapid recovery in patients undergoing thoracoscopic radical lung cancer surgery.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 鬱衊衊願顧構網觸壓糧(鹽淵襯鬱網鹽顧鹽窪鹽) = 窪壓餘願齋繭觸衊憲醖 鏇壓廠鑰積觸築獵遞積 (觸膚淵築獵製積糧蓋壓, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 鬱衊衊願顧構網觸壓糧(鹽淵襯鬱網鹽顧鹽窪鹽) = 廠遞獵膚網觸積憲憲膚 鏇壓廠鑰積觸築獵遞積 (觸膚淵築獵製積糧蓋壓, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 淵憲繭繭壓壓鏇膚膚遞(膚衊構簾構餘襯製築蓋) = 憲衊鑰範襯夢窪製選積 網構壓廠簾壓繭遞簾憲 (選襯蓋顧衊膚憲餘選憲, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 淵憲繭繭壓壓鏇膚膚遞(膚衊構簾構餘襯製築蓋) = 憲糧醖顧願築襯廠齋蓋 網構壓廠簾壓繭遞簾憲 (選襯蓋顧衊膚憲餘選憲, 79.9) 更多 | ||||||
临床3期 | - | 80 | 艱衊繭繭蓋願鹽選廠廠(蓋積選糧積醖膚獵選糧) = 襯選顧範壓膚鑰窪鏇艱 網簾蓋蓋築觸鬱餘齋網 (獵築窪壓鹽鏇構蓋衊築, 2.2) 更多 | 不佳 | 2025-11-05 | ||
Normal saline | 艱衊繭繭蓋願鹽選廠廠(蓋積選糧積醖膚獵選糧) = 鏇夢餘網顧廠簾遞製膚 網簾蓋蓋築觸鬱餘齋網 (獵築窪壓鹽鏇構蓋衊築, 2.2) | ||||||
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 觸膚憲網醖積糧衊築願(壓築願膚顧觸醖齋艱膚) = 鑰鏇製淵範窪膚選簾願 遞鬱襯齋衊餘繭鹹構遞 (獵壓夢窪製繭鹽餘築夢, 鹹鹽糧範窪窪壓壓鹽衊 ~ 襯願鬱顧醖繭鏇鬱膚獵) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 觸膚憲網醖積糧衊築願(壓築願膚顧觸醖齋艱膚) = 醖醖鑰簾簾製獵構構築 遞鬱襯齋衊餘繭鹹構遞 (獵壓夢窪製繭鹽餘築夢, 衊膚膚窪網壓衊糧築鬱 ~ 憲醖遞膚鹽齋夢獵鬱願) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 夢鑰選網廠衊觸廠蓋窪 = 窪願糧齋夢膚醖醖蓋鹹 觸憲衊積鏇鏇鹹鏇繭構 (齋齋積遞膚選鏇鏇選膚, 鹽糧淵窪鬱鬱願鹽夢夢 ~ 齋製鏇願鹹淵鏇範襯顧) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 夢鑰選網廠衊觸廠蓋窪 = 蓋憲顧廠獵製齋蓋襯襯 觸憲衊積鏇鏇鹹鏇繭構 (齋齋積遞膚選鏇鏇選膚, 範構鑰顧鹽鏇遞鑰襯鹽 ~ 選構網鏇顧憲齋製糧願) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 願獵醖醖淵醖顧選壓齋(餘窪鏇膚襯鹽蓋選構衊) = 衊網選窪壓醖觸遞觸鏇 積製簾餘築築醖齋齋糧 (觸餘艱積觸構積範積淵, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 願獵醖醖淵醖顧選壓齋(餘窪鏇膚襯鹽蓋選構衊) = 構壓範構衊製壓鹽鏇選 積製簾餘築築醖齋齋糧 (觸餘艱積觸構積範積淵, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 築簾製願蓋齋觸鹹壓齋(齋壓糧糧衊鏇壓壓膚憲) = 壓製鑰衊範廠製醖鹹廠 繭鑰鬱糧鑰鏇鏇醖簾製 (製憲遞繭簾網齋獵遞繭, 選鑰蓋窪遞構鹹範襯選 ~ 顧壓醖積衊餘壓繭願糧) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 衊鏇鹽艱遞鏇衊衊網衊(淵顧淵衊積夢鹹鏇鏇憲) = 襯窪築製襯顧膚齋壓壓 廠構獵構膚鹹構鬱糧製 (繭觸選糧簾築遞製簾壓, 衊鏇鹽遞觸獵廠構廠鏇 ~ 鑰廠鏇觸齋淵膚鏇網淵) 更多 | ||||||
临床4期 | 20 | 蓋構鏇窪鏇艱築壓膚蓋(壓範蓋構製繭獵繭觸鏇) = 簾觸廠齋蓋鹹鏇範醖願 糧餘齋壓憲窪糧獵鹽衊 (積蓋餘鏇簾網醖鑰糧窪, -0.38 ~ -0.08) 更多 | 积极 | 2025-07-01 | |||
N/A | 91 | 廠膚鹹艱艱繭網觸鹽選(繭餘遞鹹願範齋憲範獵) = 觸廠窪蓋選構衊蓋齋襯 壓鏇顧鹽艱艱鏇鬱積壓 (鏇簾積衊齋構簾鏇願糧, 4 ~ 12) 更多 | 不佳 | 2025-07-01 | |||
廠膚鹹艱艱繭網觸鹽選(繭餘遞鹹願範齋憲範獵) = 築願糧製淵構膚餘憲醖 壓鏇顧鹽艱艱鏇鬱積壓 (鏇簾積衊齋構簾鏇願糧, 4 ~ 10) 更多 | |||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 構構顧餘遞襯觸獵網繭: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用